A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 59,869 shares of BMRN stock, worth $3.99 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
59,869
Previous 65,775 8.98%
Holding current value
$3.99 Million
Previous $5.42 Million 22.29%
% of portfolio
0.02%
Previous 0.03%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$69.02 - $93.84 $407,632 - $554,219
-5,906 Reduced 8.98%
59,869 $4.21 Million
Q1 2024

May 13, 2024

BUY
$83.81 - $99.0 $185,303 - $218,889
2,211 Added 3.48%
65,775 $5.74 Million
Q4 2023

Feb 14, 2024

SELL
$76.22 - $98.51 $3.83 Million - $4.96 Million
-50,305 Reduced 44.18%
63,564 $6.13 Million
Q3 2023

Nov 09, 2023

SELL
$85.07 - $94.48 $7.31 Million - $8.12 Million
-85,947 Reduced 43.01%
113,869 $10.1 Million
Q2 2023

Aug 07, 2023

BUY
$86.68 - $100.3 $8,494 - $9,829
98 Added 0.05%
199,816 $17.3 Million
Q1 2023

May 11, 2023

BUY
$87.74 - $117.27 $643,397 - $859,940
7,333 Added 3.81%
199,718 $19.4 Million
Q4 2022

Feb 08, 2023

BUY
$80.93 - $108.63 $9.48 Million - $12.7 Million
117,079 Added 155.47%
192,385 $19.9 Million
Q3 2022

Nov 14, 2022

SELL
$82.16 - $96.94 $381,551 - $450,189
-4,644 Reduced 5.81%
75,306 $6.38 Million
Q2 2022

Aug 10, 2022

SELL
$71.48 - $86.85 $192,781 - $234,234
-2,697 Reduced 3.26%
79,950 $6.63 Million
Q1 2022

May 11, 2022

SELL
$74.28 - $92.69 $313,015 - $390,595
-4,214 Reduced 4.85%
82,647 $6.37 Million
Q4 2021

Feb 10, 2022

BUY
$71.72 - $91.47 $614,640 - $783,897
8,570 Added 10.95%
86,861 $7.74 Million
Q3 2021

Nov 10, 2021

BUY
$74.77 - $85.47 $68,937 - $78,803
922 Added 1.19%
78,291 $6.05 Million
Q2 2021

Aug 10, 2021

SELL
$75.51 - $84.79 $913,671 - $1.03 Million
-12,100 Reduced 13.52%
77,369 $6.46 Million
Q1 2021

May 14, 2021

SELL
$74.73 - $90.69 $951,462 - $1.15 Million
-12,732 Reduced 12.46%
89,469 $6.76 Million
Q4 2020

Feb 11, 2021

BUY
$72.61 - $90.2 $306,196 - $380,373
4,217 Added 4.3%
102,201 $8.96 Million
Q3 2020

Nov 12, 2020

BUY
$71.87 - $131.03 $2.55 Million - $4.65 Million
35,487 Added 56.78%
97,984 $7.46 Million
Q2 2020

Aug 13, 2020

SELL
$79.55 - $124.22 $1.22 Million - $1.91 Million
-15,362 Reduced 19.73%
62,497 $7.71 Million
Q1 2020

May 13, 2020

SELL
$71.37 - $96.85 $2.68 Million - $3.63 Million
-37,491 Reduced 32.5%
77,859 $6.58 Million
Q4 2019

Feb 14, 2020

BUY
$64.27 - $86.37 $563,904 - $757,810
8,774 Added 8.23%
115,350 $9.75 Million
Q3 2019

Nov 08, 2019

SELL
$67.4 - $85.11 $67,400 - $85,110
-1,000 Reduced 0.93%
106,576 $7.18 Million
Q2 2019

Aug 09, 2019

SELL
$80.35 - $93.9 $1.25 Million - $1.46 Million
-15,544 Reduced 12.63%
107,576 $9.21 Million
Q1 2019

May 15, 2019

BUY
$84.2 - $98.62 $4.78 Million - $5.6 Million
56,788 Added 85.61%
123,120 $10.9 Million
Q4 2018

Feb 12, 2019

SELL
$80.14 - $106.07 $1.15 Million - $1.52 Million
-14,328 Reduced 17.76%
66,332 $5.65 Million
Q3 2018

Nov 05, 2018

SELL
$93.92 - $105.72 $1.87 Million - $2.1 Million
-19,900 Reduced 19.79%
80,660 $7.82 Million
Q2 2018

Aug 14, 2018

BUY
$76.01 - $99.03 $555,937 - $724,305
7,314 Added 7.84%
100,560 $9.47 Million
Q1 2018

Apr 30, 2018

BUY
$77.67 - $92.63 $3.61 Million - $4.31 Million
46,486 Added 99.41%
93,246 $7.56 Million
Q4 2017

Feb 12, 2018

BUY
$80.76 - $95.13 $50,555 - $59,551
626 Added 1.36%
46,760 $4.17 Million
Q3 2017

Nov 13, 2017

SELL
$80.6 - $94.95 $225,679 - $265,860
-2,800 Reduced 5.72%
46,134 $4.29 Million
Q2 2017

Aug 14, 2017

BUY
N/A
48,934
48,934 $0

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Skandinaviska Enskilda Banken Ab (Publ) Portfolio

Follow Skandinaviska Enskilda Banken Ab (Publ) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

News

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.